Drug Trial Radar · NCT07256782
A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Dec 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
444
Planned (sponsor's estimate)
Start
Oct 24, 2025
Primary completion
Oct 2026
Study completion May 2028
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
QLC5508 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the safety, tolerability, pharmacokinetics and anti-tumor activity of QLC5508 in combination with other anti-cancer agents in patients with advanced solid tumor patients.
Conditions
- Advanced Solid Tumor
Interventions
QLC5508Drug
2.4 mg/kg and 2.0 mg/kg, Q3W/Q2W,administered as an IV infusion
QL1706Drug
5 mg/kg ,Q3W,administered as an IV infusion
Cisplatin/ CarboplatinDrug
Cisplatin(75 mg/m2; Q3W) / Carboplatin(AUC 5 mg/mL/min; Q3W),administered as an IV infusion
QL2107Drug
200 mg, Q3W,administered as an IV infusion
PaclitaxelDrug
175 mg/m2, Q3W,administered as an IV infusion
5-fluorouracil (5-FU)Drug
800 mg/m2,Q3W(arm:QLC5508, QL2107 and 5-FU),administered as an IV infusion;1200 mg/m2, Q2W(arm:QLC5508, Oxaliplatin, 5-FU,and leucovorin),administered as an IV infusion
OxaliplatinDrug
30 mg/m2, Q2W,administered as an IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (MTD) for combination-treatments (Phase Ib)Time frame: Up to day 21 (Q3W combination) or day 28 (Q2W combination) from the first dose
- Recommended Phase II Dose (RP2D) for combination-treatments (Phase Ib)Time frame: Up to day 21 (Q3W combination) or day 28 (Q2W combination) from the first dose
- Objective response rate (ORR) determined by investigators (Phase II)Time frame: Approximately 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai East Hospital
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.